Literature DB >> 23731739

A case of lung adenocarcinoma harboring exon 19 EGFR deletion and EML4-ALK fusion gene.

Xiaoxia Chen1, Jie Zhang, Qiong Hu, Xuefei Li, Caicun Zhou.   

Abstract

We report a man with advanced adenocarcinoma who harboring exon 19 (E746-A750del) epidermal growth factor receptor (EGFR) deletion and echinoderm microtubule-associated protein like 4-anaplastic lymphoma kinase (EML4-ALK) gene translocation in the re-biospy specimen. The patient was treated with erlotinib with a stable disease but progressed slowly, while crizotinib showed a complete response.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Acquired resistance; Adenocarcinoma; EGFR mutation; EML4-ALK fusion; Lung

Mesh：

Substances：

Year:  2013        PMID： 23731739     DOI： 10.1016/j.lungcan.2013.05.003

Source DB:  PubMed          Journal:  Lung Cancer        ISSN： 0169-5002            Impact factor:   5.705


  13 in total

1.  Adenocarcinoma of the lung with concomitant ALK fusion gene and EGFR gene mutation: A case report and literature review.

Authors:  Tao Fan; Ying-Jie Song; Xiu-Li Liu
Journal:  Mol Clin Oncol       Date:  2015-11-25

Review 2.  Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights.

Authors:  Catherine B Meador; Aaron N Hata
Journal:  Pharmacol Ther       Date:  2020-03-06       Impact factor: 12.310

3.  Poor response to gefitinib in lung adenocarcinoma with concomitant epidermal growth factor receptor mutation and anaplastic lymphoma kinase rearrangement.

Authors:  Jianya Zhou; Jing Zheng; Jing Zhao; Yihong Sheng; Wei Ding; Jianying Zhou
Journal:  Thorac Cancer       Date:  2015-03-02       Impact factor: 3.500

4.  Clinical effect of pemetrexed as the first-line treatment in Chinese patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer.

Authors:  Di Ma; Xuezhi Hao; Yan Wang; Puyuan Xing; Junling Li
Journal:  Thorac Cancer       Date:  2016-05-11       Impact factor: 3.500

5.  Responses to crizotinib and chemotherapy in patients with lung adenocarcinoma harboring a concomitant EGFR mutation and ALK gene rearrangement: A case report and review of the literature.

Authors:  Yuping Li; Shanshan Su; Guoping Cai; Quan Lin; Ying Zhou; Jinsheng Ouyang; Bicheng Chen; Junru Ye; Xiuling Wu; Chengshui Chen
Journal:  Mol Clin Oncol       Date:  2017-06-29

Review 6.  Concomitant EML4-ALK rearrangement and EGFR mutation in non-small cell lung cancer patients: a literature review of 100 cases.

Authors:  Giuseppe Lo Russo; Martina Imbimbo; Giulia Corrao; Claudia Proto; Diego Signorelli; Milena Vitali; Monica Ganzinelli; Laura Botta; Nicoletta Zilembo; Filippo de Braud; Marina Chiara Garassino
Journal:  Oncotarget       Date:  2017-04-26

7.  Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations.

Authors:  Na-Na Lou; Xu-Chao Zhang; Hua-Jun Chen; Qing Zhou; Li-Xu Yan; Zhi Xie; Jian Su; Zhi-Hong Chen; Hai-Yan Tu; Hong-Hong Yan; Zhen Wang; Chong-Rui Xu; Ben-Yuan Jiang; Bin-Chao Wang; Xiao-Yan Bai; Wen-Zhao Zhong; Yi-Long Wu; Jin-Ji Yang
Journal:  Oncotarget       Date:  2016-10-04

8.  Pulmonary Adenocarcinoma, Harboring Both an EGFR Mutation and ALK Rearrangement, Presenting a Stable Disease to Erlotinib and a Partial Response to Alectinib.

Authors:  Akira Yokoyama; Atsuhisa Tamura; Kazuko Miyakawa; Kei Kusaka; Masahiro Shimada; Takashi Hirose; Hirotoshi Matsui; Masashi Kitani; Akira Hebisawa; Ken Ohta
Journal:  Intern Med       Date:  2018-03-09       Impact factor: 1.271

9.  Synchronous Presence of EGFR, ALK Driver Mutations Along With PD L1 Overexpression in a Resected Early Stage Non-Small Cell Lung Cancer: A Case Report and Review of Literature.

Authors:  Nishitha Thumallapally; Sara Parylo; Adarsh Vennepureddy; Uroosa Ibrahim; Alisa Sokoloff
Journal:  World J Oncol       Date:  2018-05-01

10.  [Advances in Double Mutations of EGFR and ALK Gene in Non-small Cell Lung Cancer].

Authors:  Xin Wang; Diansheng Zhong
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2018-09-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.